Priority Lists
Protocol Posting of
Activations
Activation
Phase II Study of Arsenic Trioxide in Male Patients with Refractory Germ Cell Malignancies
| Study Coordinator(s) | Tomasz M. Beer, M.D., Craig R. Nichols, M.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons |
Closures
Amendments, Revisions, Memoranda
Revision #1 (GOG Revision #12)
A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma
| Participants | Members, NCORP, Surgeons, Pathologists |
Revision #3 (GOG Revision #8)
A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma.
| Study Coordinator(s) | Amy D. Tiersten, M.D. |
| Participants | NCORP, Members, Surgeons, Pathologists |
Revision #6
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Surgeons |
Amendment #1
Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
| Study Coordinator(s) | Howard (Jack) West, M.D., Ralph B. Vance, M.D., Wilbur A. Franklin, M.D., Derick H.M. Lau, M.D.,Ph.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #3
Repository for Paraffin Embedded Tissues from Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., Heinz- Josef Lenz, M.D., Joseph A. Holden, M.D., Kurt H. Albertine, Ph.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
Revision #5
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach.
| Study Coordinator(s) | James H. Doroshow, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP |
Revision #10
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III.
| Study Coordinator(s) | L. Michael Glode, M.D., Maha H.A. Hussain, M.D., Gregory P. Swanson, M.D., David P. Wood Jr., M.D., Wael A. Sakr, M.D. |
| Participants | Members, NCORP, Affiliates, UCOP, Medical Oncologists, Surgeons, Radiation Oncologists, Pathologists, EPP, CALGB, CTSU Institutions in the United States |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required